Blog Posts
agenus

Agenus announced new data highlighting BOT/BAL across multiple lines of treatment in Colorectal Cancer

Agenus shared on LinkedIn:

“Today, we announced new data highlighting BOT/BAL across multiple lines of treatment in Colorectal Cancer.

Find the details of our five ASCO GI presentations here.”

Further Reading:

Three decades of pioneering in Immune Oncology – Agenus

Botensilimab: A Revolutionary Fc-Enhanced CTLA-4 Inhibitor Transforming Cancer Immunotherapy

Botensilimab’s mechanism of action and potential in addressing treatment-resistant cancers

New Paper Alert! Promising Results for MSS Colorectal Cancer Treated with Balstilimab and Botensilimab

Agenus has Announced Five Presentations at 2025 ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers

Agenus BOT/BAL BOT/BAL immunotherapy cancer Headlines OncoDaily Oncology